ResearcherFiona Stanley Fremantle Hospitals GroupNo recent work listed

Chris Lomma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2615-1467; OpenAlex author ID A5000437212. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2023: 2 papers

Papers 2

ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenoc… Co-author DOI 10.1016/j.esmogo.2023.07.001 ↗
Pancreatic adenocarcinoma with brain metastases. First author DOI 10.1136/bcr-2022-253557 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ngie Law · 1 shared paper, 2023 · strength 0.39
- Paper Pancreatic adenocarcinoma with brain metastases. DOI 10.1136/bcr-2022-253557 ↗
Andrew Peter Dean · 1 shared paper, 2023 · strength 0.12
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001 ↗
Joanna Lee · 1 shared paper, 2023 · strength 0.12
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001 ↗
Val Gebski · 1 shared paper, 2023 · strength 0.12
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001 ↗
Timothy Jay Price · 1 shared paper, 2023 · strength 0.12
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001 ↗
Lorraine A. Chantrill · 1 shared paper, 2023 · strength 0.12
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001 ↗
Christos Stelios Karapetis · 1 shared paper, 2023 · strength 0.12
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001 ↗
Matthew Burge · 1 shared paper, 2023 · strength 0.12
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001 ↗
Niall Christopher Tebbutt · 1 shared paper, 2023 · strength 0.12
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001 ↗
Marion Harris · 1 shared paper, 2023 · strength 0.12
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001 ↗
Belinda Lee · 1 shared paper, 2023 · strength 0.12
- Paper ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 i… DOI 10.1016/j.esmogo.2023.07.001 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.